Amgen Secures EU Nod for Imdylltra in Lung Cancer Indication
AMGN wins EU approval for Imdylltra in extensive-stage small cell lung cancer after phase III data showed a 40% reduction in death risk.
Open original sourceLoading market dashboard
AMGN wins EU approval for Imdylltra in extensive-stage small cell lung cancer after phase III data showed a 40% reduction in death risk.
Open original source